Detailed notes on Pulmonary artery hypertension in systemic sclerosis: Screening, diagnosis and recent trends in treatment. From rheumatology textbooks and major journals

Reading File

Finding Sources

Searching PubMed

"pulmonary arterial hypertension" AND "systemic sclerosis" AND screening

Searching the Web

pulmonary arterial hypertension systemic sclerosis screening diagnosis treatment 2024 2025 guidelines

Finding Sources

Reading Article

PMID: 41708122

Reading Article

PMID: 41085415

Reading Web Page

https://pmc.ncbi.nlm.nih.gov/articles/PMC12536151

Finding Sources

Reading File

Searching PubMed

"systemic sclerosis" AND "pulmonary arterial hypertension" AND sotatercept

Reading File

Reading Article

PMID: 38531379

Reading Article

PMID: 40905396

Finding Sources

Reading Article

PMID: 41594679

Reading File

Loading Image

I now have comprehensive data from multiple major textbooks and recent journals to compile detailed notes. Let me write the full structured notes.

Pulmonary Arterial Hypertension in Systemic Sclerosis: Detailed Clinical Notes

Sources: Firestein & Kelley's Textbook of Rheumatology (2022), Rheumatology 2-Vol Set (Elsevier, 2022), Goldman-Cecil Medicine (2022), Murray & Nadel's Textbook of Respiratory Medicine, Braunwald's Heart Disease (15th ed.), Fishman's Pulmonary Diseases; supplemented with recent literature (2024-2026).

1. Epidemiology and Clinical Significance

SSc-PAH is one of the most common and most clinically important manifestations of systemic sclerosis. PAH occurs in 7-15% of SSc patients and is a leading cause of disease-related death, accounting for approximately 20-30% of SSc mortality. It most commonly complicates limited cutaneous SSc (lcSSc/CREST), although diffuse cutaneous SSc patients with nucleolar ANA patterns (anti-U3-RNP, anti-Th/To) are also at substantial risk.

Compared to idiopathic PAH (iPAH), SSc-PAH carries a significantly worse prognosis: 3-year survival in contemporary rheumatology-based registry data (PHAROS study) reaches 75%, which is poorer than iPAH at similar time points. This reflects more aggressive vascular remodeling, co-existing cardiac fibrosis, impaired RV-PA coupling, and poor responses to conventional vasodilator therapies.

Fishman's Pulmonary Diseases: "PAH (WHO Group 1) occurs in approximately 10% of cases of systemic sclerosis and is primarily seen in the limited cutaneous form (CREST syndrome)."
Goldman-Cecil Medicine, p. 814: "The prevalence of pulmonary arterial hypertension [in SSc] is in the range of 7 to 12%."

2. Pathophysiology

2a. Vascular Pathology

SSc-PAH involves progressive obliteration of the pulmonary microvasculature through:

Obliterative intimal lesions with matrix accumulation (see histology below)
Smooth muscle hyperplasia and medial thickening
Adventitial expansion
Endothelial dysfunction with reduced nitric oxide (NO) and prostacyclin production, and increased endothelin-1 (ET-1) secretion

Pulmonary artery changes in SSc-PAH - elastin stain showing intimal thickening on the luminal side of the elastic lamina in a small pulmonary artery

Histology: Pulmonary artery changes in SSc-PAH. Elastin stain showing intimal thickening with matrix accumulation on the luminal side of the elastic lamina. Note only mild interstitial fibrosis - Rheumatology 2-Vol (Elsevier, 2022)

Key distinctions from iPAH:

Pulmonary veno-occlusive disease (PVOD) is rare in iPAH but common in SSc-PAH, contributing to poor response to vasodilators
Plexogenic lesions are rare in SSc-PAH (unlike iPAH)
Pulmonary thrombosis is more prevalent in SSc-PAH
Patients with SSc-PAH show impaired RV-PA coupling at much lower RV afterload levels than iPAH, linked to increased interstitial RV cardiac fibrosis
Rheumatology 2022 (Elsevier), p. 6565: "Pulmonary venoocclusive disease, which is rare in idiopathic PAH, occurs frequently in SSc-PAH, along with evidence of pulmonary thrombosis."

2b. Immune and Molecular Mechanisms

The pathogenesis involves:

Immune dysregulation: T-cell activation, B-cell dysregulation, autoantibody production
Chronic inflammation: IL-6, IL-8, VEGF, TGF-β overexpression
Activin/TGF-β pathway dysregulation: now a recognized therapeutic target
BMPR2 pathway impairment (as in iPAH), contributing to impaired vascular repair
Endothelin-1 excess: a potent vasoconstrictor and proliferative mediator - the basis for ERA therapy

Recent evidence (Birnhuber A et al., Curr Opin Pulm Med 2026 [PMID: 42267527]) highlights preclinical advances in understanding SSc-specific vascular-immune interactions and their therapeutic implications.

3. Screening

3a. Who to Screen

All SSc patients should undergo annual screening for PAH, regardless of cutaneous subtype or symptom status. Current guidelines recommend formal screening using objective testing. High-risk features that should heighten vigilance:

Risk Factor	Significance
Longer disease duration (>3 years)	Increased cumulative risk
Older age	Independent predictor
Severe Raynaud's/digital ulcers	Reflects vasculopathy severity
Multiple/large telangiectasias	Marker of vascular disease extent
Isolated DLCO decline	Surrogate of pulmonary vascular disease
FVC%/DLCO% ratio >1.6	Suggests vascular >parenchymal disease
NT-proBNP elevation (>395 pg/mL)	Right heart strain
Anti-centromere antibody	Strongly associated with lcSSc-PAH
Anti-U1-RNP, U3-RNP, Th/To antibodies	Additional PAH risk markers
Anti-Ro52 antibodies	Emerging risk marker

Firestein & Kelley's Textbook of Rheumatology, p. 1859 (Fig. 85.12 source)

3b. Screening Tests

1. Pulmonary Function Tests (PFTs)

DLCO is typically significantly reduced, often to <40-60% predicted, frequently years before PAH becomes manifest
The FVC%/DLCO% ratio >1.6 is a strong clue to pulmonary vascular disease (as opposed to ILD, where both FVC and DLCO fall)
An isolated low DLCO without significant restriction or obstruction should trigger further evaluation
Rheumatology 2022 (Elsevier): "The diffusing capacity for carbon monoxide (DLCO) almost always is significantly decreased long before PAH develops, often as low as 40%."

2. Echocardiography (ECHO)

First-line noninvasive screening tool; recommended annually in all SSc patients
The 2022 ESC/ERS guidelines updated the echocardiographic threshold: TRV >2.8 m/s (previously 2.9 m/s) is now the cut-off for intermediate-high probability of PH, especially combined with other echocardiographic signs
RVSP >45 mmHg predicts PAH by RHC with ~95% accuracy
Additional echo signs of PH: RV/LV basal diameter ratio ≥1.0, interventricular septal flattening, TAPSE/sPAP ratio <0.55 mm/mmHg, PA diameter >25 mm, RVOT acceleration time <105 ms
Echo alone carries important false-positive and false-negative rates in SSc, necessitating RHC for confirmation

3. Biomarkers

NT-proBNP: even modest elevations >395 pg/mL indicate right heart strain and should trigger evaluation
BNP: used alongside NT-proBNP for risk stratification
FVC%/DLCO% ratio: composite PFT biomarker
Autoantibodies: anti-centromere, U1-RNP, U3-RNP, Th/To, Ro52 as risk stratification tools

4. ECG

Can be normal early; as disease progresses shows RV hypertrophy, right axis deviation, right heart strain pattern

3c. The DETECT Algorithm

The DETECT algorithm is the most evidence-based, validated screening tool for SSc-PAH, specifically designed for SSc patients at increased risk. It follows a two-step approach:

Eligibility criteria: SSc patients with:

Disease duration >3 years
DLCO <60% predicted
FVC ≥40% predicted (excludes severe ILD)

Step 1 - Combines 6 clinical/lab variables to generate a risk score:

FVC%/DLCO% ratio
NT-proBNP
Serum urate
Any telangiectasias
Anti-centromere antibody
Right axis deviation on ECG → If score exceeds threshold: proceed to echocardiography

Step 2 - ECHO variables:

TRV (tricuspid regurgitation velocity)
Right atrial area → If combined score exceeds threshold: refer for RHC

The original DETECT study (Coghlan et al., Ann Rheum Dis 2014; 488 patients, 31% had PH on RHC, 19% had PAH) demonstrated only 4% missed PAH diagnoses with this algorithm.

Murray & Nadel's Respiratory Medicine: "These analyses identified eight clinical variables that, when applied in a two-step algorithm, predicted the presence of PH on RHC with a low rate (4%) of missed PAH diagnoses."
Firestein & Kelley's: "DETECT has been validated across many general scleroderma cohorts exhibiting a consistently high sensitivity and negative predictive value, but modest specificity and positive predictive value."

Limitations: High false-positive rate may lead to unnecessary RHC referrals. The DETECT algorithm will also increase identification of "borderline PAH" (mPAP 21-24 mmHg) for which approved therapies are lacking.

2025 Consensus Update (Sari et al., Anatol J Cardiol 2025 [PMID: 41085415], multidisciplinary group of 10 rheumatologists, 4 cardiologists, 3 pulmonologists): Recommends prioritizing echocardiography-based screening for SSc patients and those with CTD overlap features of SSc. Insufficient data to recommend routine screening in asymptomatic non-SSc CTD patients without SSc overlap.

3d. ASIG (Australian Scleroderma Interest Group) Algorithm

The ASIG algorithm is an alternative two-step tool using a different set of variables. It performs comparably to DETECT in external validation cohorts. The choice between DETECT and ASIG depends on institutional preference and resource availability.

4. Diagnosis

4a. Hemodynamic Definition

The 2022 ESC/ERS guidelines updated PAH definitions:

Mean pulmonary arterial pressure (mPAP) ≥20 mmHg (lowered from >25 mmHg)
Pulmonary capillary wedge pressure (PCWP) ≤15 mmHg
Pulmonary vascular resistance (PVR) >2 Wood Units (lowered from ≥3 WU)

All three criteria must be met on right heart catheterization (RHC) - the gold standard for PAH diagnosis.

Firestein & Kelley's, p. 1859: "It is now defined as resting mean pulmonary arterial pressure equal to or greater than 20 mm Hg, with normal pulmonary capillary wedge pressure equal to or less than 15 mm Hg and pulmonary vascular resistance >3 wood units, although this threshold has been recently lowered to >2 wood units in the 2022 ESC/ERS guidelines."

4b. Right Heart Catheterization (RHC)

RHC is mandatory for diagnosis. Indications for RHC referral in SSc:

eRVSP >45 mmHg on ECHO
Unexplained dyspnea with eRVSP 35-45 mmHg + additional echo signs
DETECT/ASIG algorithm threshold reached
Low DLCO + normal FVC + elevated BNP/NT-proBNP, even with normal ECHO
Dyspnea without ILD and progressive DLCO decline

RHC provides:

Direct measurement of mPAP, PCWP, cardiac output, PVR
Differentiation of PAH from left heart disease (group 2 PH) - especially important in SSc where diastolic dysfunction and PVOD co-exist
Vasodilator challenge (acute vasoreactivity testing) - though acute response is rare in SSc-PAH and calcium-channel blocker therapy is generally not appropriate

4c. Distinguishing PH Types in SSc

SSc patients can develop multiple PH phenotypes simultaneously or sequentially:

Group 1 PAH (pure pulmonary vascular disease) - most common in lcSSc
Group 2 PH (left heart disease) - diastolic dysfunction, elevated PCWP
Group 3 PH (ILD-associated) - must have significant ILD + mPAP >35 mmHg or PVR >5 WU
PVOD phenotype - SSc-specific, poor prognosis, risk of pulmonary edema with vasodilators

This distinction critically affects treatment. Vasodilators may worsen group 2 PH or PVOD.

4d. Additional Diagnostic Investigations

HRCT chest: assess for ILD (NSIP pattern most common in SSc), exclude significant fibrosis driving group 3 PH; also can show PA enlargement
V/Q scan: exclude chronic thromboembolic PH (group 4) - important to rule out in all patients
6-minute walk test (6MWT): baseline functional assessment; poor correlation with hemodynamic severity in SSc compared to iPAH
Cardiopulmonary exercise testing (CPET): may improve diagnostic accuracy, especially for "exercise-induced PH" (mPAP >30 mmHg on exercise RHC); role not yet standardized
Cardiac MRI: identifies subclinical RV dysfunction and myocardial fibrosis
Nailfold capillaroscopy: "late" SSc pattern (avascular areas, giant capillaries) correlates with end-organ vascular disease including PAH (Ickinger et al., Best Pract Res Clin Rheumatol 2026 [PMID: 41826085])

5. Clinical Approach (Flowchart)

Approach to scleroderma-associated PAH showing risk factors, annual ECHO screening, DETECT algorithm triggers, RHC criteria, and treatment algorithm by functional class

Fig. 85.12 from Firestein & Kelley's Textbook of Rheumatology: Approach to scleroderma-associated PAH. Left panel shows risk factors; center shows annual assessment pathway; right panel shows treatment by WHO functional class. 6MWD = 6-minute walk distance; ERA = endothelin receptor antagonist; PDE5i = phosphodiesterase-5 inhibitor; PRA = prostacyclin IP receptor agonist.

6. Risk Stratification at Diagnosis and Follow-Up

The 2022 ESC/ERS guidelines and the 7th WSPH (2024) recommend a 4-strata risk stratification at diagnosis and every 3-6 months:

Low risk: FC I-II, 6MWD >440 m, NT-proBNP <300 ng/L, low/normal RV function, mPAP <35-40 mmHg, PVR <5 WU
Intermediate-low risk
Intermediate-high risk
High risk: FC IV, 6MWD <165 m, NT-proBNP >1400 ng/L, pericardial effusion, CI <2.0 L/min/m², RA area >26 cm²

SSc-PAH patients tend to present at higher risk categories than iPAH, partly due to diagnostic delay.

Risk stratification guides treatment escalation:

If not achieving low-risk at 3-6 months: escalate therapy
High-risk category: consider listing for lung transplant

7. Treatment

7a. General Principles

Treatment of SSc-PAH follows general PAH management guidelines, but SSc patients respond less well to vasodilator-based therapies compared to iPAH patients. This reflects the underlying vasculopathy combined with fibrosis, PVOD, and RV myocardial disease. The multidisciplinary approach is especially important in SSc, combining PH specialist input with rheumatology.

Rheumatology 2022 (Elsevier): "Scleroderma patients do not respond as well to these many treatments compared to those with idiopathic PAH. Thus in scleroderma, once the diagnosis of PAH is confirmed by RHC, treatment with at least one drug should be instituted."

Acute vasoreactivity testing is rarely positive in SSc-PAH; calcium-channel blockers are generally contraindicated.

7b. Conventional Vasodilator Therapies

Three main pharmacological pathways are targeted:

Endothelin Receptor Antagonists (ERAs)

Drug	Selectivity	Route	Dosing	Key Adverse Effects
Bosentan	Non-selective (ETA+ETB)	Oral	62.5 mg BD x 4 wks, then 125 mg BD	LFT elevation (10%), teratogenic, fluid retention, reduces oral anticoagulant effect
Ambrisentan	ETA-selective	Oral	5-10 mg OD	Teratogenic, fluid retention, peripheral edema
Macitentan	Non-selective (tissue-specific)	Oral	10 mg OD	Teratogenic, fluid retention, anemia

All approved for SSc-PAH based on RCT data.

PDE-5 Inhibitors (Nitric Oxide Pathway)

Drug	Route	Dosing	Comments
Sildenafil	Oral	20 mg TDS	Well tolerated; headache, visual disturbance
Tadalafil	Oral	40 mg OD	Longer duration of action

Soluble Guanylate Cyclase (sGC) Stimulator

Drug	Route	Comments
Riociguat	Oral 2.5 mg BD	Cannot be used with PDE5i; reserved for severe disease or PDE5i failure

Prostacyclin Pathway

Drug	Route	Dosing	Comments
Epoprostenol (prostacyclin)	Continuous IV	Titrated	Gold-standard for FC IV; only prostacyclin with RCT specifically in SSc-PAH showing improved 6MWD, functional class, hemodynamics
Treprostinil	SC/IV/inhaled/oral	Titrated	SC site pain; less abrupt deterioration than epoprostenol if interrupted
Iloprost	Inhaled	6-9x daily	Licensed for PAH
Selexipag (IP receptor agonist)	Oral	BD	GRIPHON trial included CTD-PAH; recently approved

"One high-quality RCT in patients with SSc indicates that continuous intravenous epoprostenol improves exercise capacity, functional class, and haemodynamic measures in SSc-PAH. Intravenous epoprostenol should be considered for the treatment of patients with severe SSc-PAH (class III and IV)." - Rheumatology 2022 (Elsevier)

7c. Combination Therapy - Key Trials

AMBITION Trial (Ambrisentan + Tadalafil):

Initial combination vs. monotherapy in treatment-naive PAH
Sub-analysis of CTD-PAH/SSc-PAH patients:
- Risk of clinical failure 52% lower with combination vs. monotherapy in CTD-PAH (HR 0.483)
- 54% lower in SSc-PAH specifically (HR 0.463)
Combination ambrisentan + tadalafil is now the preferred initial strategy for most SSc-PAH patients
Rheumatology 2022 (Elsevier), p. 2964

Current recommendation: Most SSc-PAH patients with FC II-III should be initiated on upfront combination ERA + PDE5i rather than sequential monotherapy.

EDITA Study (Early Treatment in Borderline PAH):

Ambrisentan in SSc patients with mildly elevated mPAP (21-24 mmHg) - to assess benefit of early intervention in "borderline" PAH
Important in context of lowered diagnostic threshold
Rheumatology 2022 (Elsevier), p. 2979

Bosentan in SSc-PAH (2024 Meta-Analysis):

Bearzi P et al., Clin Exp Rheumatol 2024 [PMID: 38819960]: Bosentan reduces echocardiographic systolic PAP in SSc-related PH

7d. Sotatercept - Major Recent Advance

Sotatercept is a fusion protein acting as an activin signaling inhibitor (targeting the TGF-β/activin/BMPR2 pathway), approved in 2024 by the FDA for PAH.

Mechanism: Sequesters activin ligands (particularly activin A) that drive vascular smooth muscle proliferation and remodeling
STELLAR trial: Demonstrated significant improvement in 6MWD, hemodynamics, and clinical worsening in patients already on background dual/triple PAH therapy
ZENITH trial (Humbert M et al., NEJM 2025): Sotatercept in high-risk PAH patients showed markedly improved outcomes [PMID referenced in Villa et al. 2026]
SSc-PAH patients were included in these trials; the activin pathway is particularly relevant given the pro-fibrotic milieu in SSc
SSc-PAH-specific data are emerging (NCT06865118 observational protocol 2025)
Current 2024 7th WSPH treatment algorithm incorporates sotatercept as an add-on therapy for patients not at low risk despite dual therapy

"Novel therapeutic targets such as the activin/TGF-β pathway have been incorporated into updated treatment algorithms. Although CTD-PAH remains associated with worse outcomes than idiopathic PAH, recent advances in screening, risk assessment, and targeted therapies have begun to improve the trajectory of the disease." - CTD-PAH practical review 2025 (PMC12536151)

Villa A et al. (Eur Respir Rev 2026, PMID: 41708122): A 2026 systematic review specifically on SSc-PAH management identified critical gaps: lack of SSc-focused trials, heterogeneity in hemodynamic severity, and exclusion of key comorbidities (ILD) from trials.

7e. Immunosuppressive Therapy in SSc-PAH

Unlike SLE-associated PAH (which can respond dramatically to immunosuppression), SSc-PAH has a predominantly fibrotic/obliterative vasculopathy and shows limited responsiveness to immunosuppressants. However:

Cyclophosphamide, mycophenolate mofetil: Limited role; may benefit inflammatory phenotypes or overlap CTD-PAH
Rituximab (anti-CD20): Emerging evidence; Touil A et al. systematic review (Expert Rev Respir Med 2026, PMID: 40905396): RTX appeared effective and safe in CTD-PH including SSc cases; primarily prospective data from Russia and USA; improvement in clinical/paraclinical parameters; limited to 6 studies
IL-6 receptor inhibitors (tocilizumab): Under investigation given IL-6's role in vascular remodeling in SSc
Glucocorticoids: Low-dose may have a role in inflammatory phenotypes but high-dose steroids risk SSc renal crisis

Yokoyama et al. (Biomolecules 2026, PMID: 41594679): "Immune-targeted therapies such as glucocorticoids, cyclophosphamide, mycophenolate mofetil, rituximab, and IL-6 receptor inhibitors may benefit inflammation-dominant PAH phenotypes, while fibrotic phenotypes continue to demonstrate limited responsiveness."

7f. 7th WSPH 2024 Treatment Algorithm

The 2024 7th World Symposium on Pulmonary Hypertension recommended:

Initial risk stratification (4-strata model)
Low/intermediate-low risk (FC I-II): Upfront dual therapy (ERA + PDE5i; ambrisentan + tadalafil preferred)
Intermediate-high/high risk (FC III-IV): Upfront dual or triple therapy; consider adding prostacyclin pathway agent early; IV epoprostenol for FC IV
Re-assess at 3-6 months: If not achieving low risk, escalate
Sotatercept: Add-on for patients not at low risk on background oral therapy (per STELLAR/ZENITH data)
Lung transplant referral: Failed maximal medical therapy

For SSc-PAH specifically, given the known poor response:

Lower threshold for early combination therapy
Lower threshold for escalation
Comorbidities (ILD, cardiac fibrosis, GI disease) must be actively managed alongside PAH therapy
Avoid acute vasoreactivity testing with calcium-channel blockers

7g. Surgical/Interventional Options

Balloon pulmonary angioplasty (BPA): For CTEPH (Group 4); not indicated in SSc-PAH group 1
Atrial septostomy: Rarely used; may provide palliative benefit in refractory high-risk PAH
Lung transplant: Considered when PAH therapy fails; outcomes in SSc are complicated by extrapulmonary SSc disease (esophageal dysmotility, bowel disease, systemic fibrosis); careful patient selection required

8. Prognosis and Follow-Up Monitoring

Prognostic factors in SSc-PAH (worse than iPAH):

Older age at diagnosis
Worse baseline hemodynamics (lower CI, higher PVR)
Lower 6MWD
Elevated NT-proBNP
FC III/IV at diagnosis
RV dysfunction (TAPSE, tricuspid annular plane systolic excursion)
Impaired RV-PA coupling (TAPSE/sPAP ratio)
Co-existing ILD

Follow-up monitoring (every 3-6 months):

ECHO + TRV, TAPSE, RA area, RV/LV ratio
6-minute walk test
NT-proBNP/BNP
WHO functional class
Blood tests: FBC, LFTs (for bosentan), renal function
Repeat RHC if clinical deterioration or escalation decision needed
Annual PFT

9. Summary of Key Points

Topic	Key Points
Prevalence	7-15% of all SSc; leading cause of SSc mortality
Subset	Mainly lcSSc; also diffuse SSc with nucleolar ANA
Prognosis	Worse than iPAH; 3-year survival ~75% (PHAROS)
Pathology	Obliterative intimal lesions, PVOD, no plexiform lesions
Screening tool	DETECT algorithm (2-step), annual ECHO, PFTs, biomarkers
Diagnosis	RHC: mPAP ≥20 mmHg, PCWP ≤15 mmHg, PVR >2 WU (2022 ESC/ERS)
Vasoreactivity	Rarely positive; CCBs generally not used
Initial treatment	Upfront combination ERA + PDE5i (ambrisentan + tadalafil; AMBITION data)
Severe disease	IV epoprostenol + combination oral therapy
New agent	Sotatercept (activin inhibitor, 2024 FDA-approved) - add-on therapy
Immunosuppression	Limited role in SSc-PAH; rituximab emerging (CTD-PAH reviews)
Transplant	Considered in refractory cases; careful patient selection

Key References

Textbooks:

Firestein & Kelley's Textbook of Rheumatology, 2-Volume Set (2022), Chapter 85
Rheumatology, 2-Volume Set (Elsevier, 2022), Chapter 150/152
Goldman-Cecil Medicine, International Edition (2022), Chapter 69
Murray & Nadel's Textbook of Respiratory Medicine (6th ed.), Chapter 83/84
Braunwald's Heart Disease (15th ed.), Chapter 13

Key Recent Literature:

Villa A et al. "Management of pulmonary arterial hypertension in systemic sclerosis: from classical treatments to new horizons." Eur Respir Rev 2026. [PMID: 41708122] - Systematic review identifying SSc-PAH management gaps
Sari A et al. "Screening for Pulmonary Hypertension in Connective Tissue Diseases: Literature Review and Multidisciplinary Consensus Statement." Anatol J Cardiol 2025. [PMID: 41085415]
Cullivan S et al. "Pulmonary Hypertension in Systemic Sclerosis." Semin Respir Crit Care Med 2024. [PMID: 38531379]
Yokoyama Y et al. "Connective Tissue Disease-Associated PAH: Current Therapeutic Strategies and Future Prospects." Biomolecules 2026. [PMID: 41594679]
Touil A et al. "Rituximab treatment for CTD-associated pulmonary hypertension." Expert Rev Respir Med 2026. [PMID: 40905396]
Bearzi P et al. "Bosentan effect on echocardiographic systolic PAP in SSc-related PH." Clin Exp Rheumatol 2024. [PMID: 38819960]
Coghlan JG et al. "Evidence-based detection of PAH in systemic sclerosis: the DETECT study." Ann Rheum Dis 2014;73:1340-1349. (Foundation screening study)
Humbert M et al. "2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension." Eur Respir J 2023;61:2200879.

Discuss in detail about the various trials in the management of ANCA associated Vasculitis. From journals and rheumatology textbooks

Finding Sources

Searching PubMed

"ANCA-associated vasculitis" AND "clinical trial"

Searching the Web

ANCA associated vasculitis clinical trials 2024 2025 avacopan rituximab maintenance treatment guidelines

Finding Sources

Searching PubMed

"ANCA vasculitis" AND "maintenance" AND "rituximab"

Searching PubMed

"ANCA vasculitis" AND "plasma exchange" AND "cyclophosphamide"

Reading File

Reading Article

PMID: 38123922

Reading Article

PMID: 40720835

Finding Sources

Reading File

Searching PubMed

"PEXIVAS" AND "plasma exchange" AND vasculitis

Reading File

Finding Sources

Reading Article

PMID: 36155131

Reading Article

PMID: 38251577

Reading File

Finding Sources

Searching PubMed

"MAINRITSAN" OR "RITAZAREM" AND "ANCA vasculitis" AND rituximab maintenance

Reading File

Reading Web Page

https://rheumnow.com/news/2025-bsr-recommendations-anca-asso…

Reading File

Searching PubMed

"ANCA vasculitis" AND "mepolizumab" AND eosinophilic granulomatosis

Here are your comprehensive notes on clinical trials in the management of ANCA-associated vasculitis, compiled from rheumatology and nephrology textbooks plus the major trial literature.

Clinical Trials in the Management of ANCA-Associated Vasculitis

Sources: Firestein & Kelley's Textbook of Rheumatology (2022), Comprehensive Clinical Nephrology 7th Ed., Brenner & Rector's The Kidney, NKF Primer 8th Ed., Goldman-Cecil Medicine (2022), Harrison's Principles 22nd Ed. (2025); supplemented by major trial publications and 2025 BSR / 2022 KDIGO / 2022 EULAR guidelines.

1. Background and Treatment Framework

AAV encompasses GPA (Granulomatosis with Polyangiitis), MPA (Microscopic Polyangiitis), and EGPA (Eosinophilic Granulomatosis with Polyangiitis). Before immunosuppressive therapy, most patients died within 1 year. With treatment, 5-year patient survival reaches 65-75%, though adverse events from therapy remain a leading cause of death in the first year.

Treatment follows a three-phase strategy:

Induction of remission (intensive phase, 3-6 months)
Maintenance of remission (2-4 years)
Treatment of relapse

The major clinical questions addressed by trials:

Which immunosuppressant and route for induction (CYC vs. RTX; oral vs. IV CYC)?
What is the role of plasma exchange?
How much glucocorticoid is necessary?
Which agent for maintenance and for how long?
Can glucocorticoids be replaced (avacopan)?
Disease-specific agents for EGPA?

Remission is induced in 75-90% of patients, but relapse is common (25-50%), demanding robust maintenance strategies.

2. Induction Trials

CYCLOPS Trial - IV vs. Oral Cyclophosphamide

Parameter	Detail
Study	CYCLOPS (de Groot et al., ARD 2009) - European Vasculitis Study Group
Design	Multicenter RCT
Population	149 newly diagnosed GPA/MPA, GFR >15 mL/min
Intervention	IV pulse CYC (0.35-0.5 g/m² every 2-3 weeks) vs. oral CYC 2 mg/kg/day, both × 3-6 months + GC
Primary endpoint	Time to remission
Result	Comparable remission rates; IV pulse: significantly lower cumulative CYC dose (8.2 g vs. 15.9 g); leukopenia less common (35% vs. 51%)
Long-term	Higher relapse rate observed with IV CYC at 18-month follow-up
Conclusion	IV pulse CYC is preferred for reducing cumulative dose/toxicity; oral CYC may offer marginally lower relapse rates in some settings

Comprehensive Clinical Nephrology 7th Ed.: "IV cyclophosphamide has similar remission rates as oral cyclophosphamide while reducing the total cyclophosphamide dose."

NORAM Trial - Methotrexate vs. Cyclophosphamide in Limited Disease

Parameter	Detail
Study	NORAM (de Groot et al., ARD 2005)
Design	RCT, European Vasculitis Study Group
Population	Early limited GPA/MPA without severe organ involvement; creatinine <150 µmol/L
Intervention	MTX (15 mg/wk escalating to 25 mg/wk) vs. oral CYC 2 mg/kg/day × 12 months
Result	MTX remission comparable to CYC at 6 months (89.8% vs. 93.5%, NS); but slower onset, especially with pulmonary disease
Relapse rate	MTX: 69.5% vs. CYC: 46.5% - significantly higher
Conclusion	MTX acceptable for non-severe, non-renal AAV; NOT for renal disease; higher relapse rate limits use

RAVE Trial - Rituximab vs. Cyclophosphamide (Induction) - Landmark

Parameter	Detail
Study	RAVE (Stone et al., NEJM 2010)
Design	Phase III, randomized, double-blind, double-dummy, noninferiority RCT
Population	197 patients with GPA (75%) or MPA (24%), newly diagnosed AND relapsing
Intervention	RTX 375 mg/m² IV × 4 weekly doses vs. oral CYC 2 mg/kg/day (×3 months then AZA); both with GC taper
Primary endpoint	Complete remission (BVAS/WG = 0 + completed prednisone taper) at 6 months
Overall result	RTX 64% vs. CYC 55% (p = 0.21); noninferiority met (p < 0.001)
Relapsing disease subgroup	RTX superior: 67% vs. 42% remission (p = 0.01)
PR3-ANCA subgroup	RTX trend toward superiority
18-month extension	Specks et al., NEJM 2013: sustained benefit maintained; RTX still superior for relapsing disease
Adverse events	Similar between groups
Conclusion	RTX non-inferior to CYC for induction overall; superior for relapsing disease and PR3-ANCA patients; established RTX as first-line alongside CYC

Rheumatology 2022 Elsevier: "Subgroup analysis showed that RTX was more efficacious than cyclophosphamide in patients with relapsing disease at baseline."

RITUXVAS Trial - Rituximab vs. Cyclophosphamide in Renal AAV

Parameter	Detail
Study	RITUXVAS (Jones et al., NEJM 2010)
Design	RCT, European Vasculitis Study Group
Population	44 patients with new-onset ANCA-associated renal vasculitis; GFR <45 mL/min (or dialysis-dependent)
Intervention	RTX 375 mg/m² × 4 + 2 IV CYC pulses (days 1 and 15) vs. IV CYC × 3-6 months + AZA; both with GC
Primary endpoint	Sustained remission at 12 months
Result	RTX group 76% vs. control 82% sustained remission (p = 0.68) - no significant difference
Adverse events	Similar early severe AEs
Conclusion	RTX comparable to IV CYC for severe renal AAV; validated FDA/EMA approval for renal disease

RAVE vs. RITUXVAS - Key Differences:

Feature	RAVE	RITUXVAS
RTX dose	375 mg/m² × 4 alone	375 mg/m² × 4 + 2 CYC pulses
Comparator	Oral CYC then AZA	IV CYC then AZA
Population	New + relapsing	New onset, severe renal only
Primary outcome	Non-inferior	Non-inferior
Relapse benefit	Yes (for relapsing disease)	Not powered

WGET Trial - Etanercept (TNF Inhibitor) in GPA

Parameter	Detail
Study	WGET (Stone et al., NEJM 2003)
Design	RCT (n = 180)
Intervention	Etanercept added to standard therapy vs. standard therapy alone
Result	No benefit in remission or relapse reduction; 6 solid tumors in etanercept arm vs. 0 in placebo
Conclusion	TNF inhibitors are contraindicated in GPA/AAV - increased malignancy risk

3. Plasma Exchange Trials

MEPEX Trial - Plasma Exchange vs. IV Methylprednisolone

Parameter	Detail
Study	MEPEX (Jayne et al., JASN 2007)
Design	RCT, European Vasculitis Study Group
Population	137 patients with severe ANCA-associated GN; serum creatinine >5.8 mg/dL (dialysis-risk)
Intervention	Plasma exchange (7 sessions over 14 days) vs. IV methylprednisolone 3 g; both with oral CYC + GC
Primary endpoint	Renal recovery (dialysis independence) at 3 months
Result	PE: 69% renal recovery vs. pulse MP: 49% (p = 0.02) - PE significantly superior for early renal recovery
5-year follow-up	No significant difference in ESKD-free survival (45% vs. 43%); limited by sample size
Conclusion	PE improves early renal recovery in dialysis-dependent AAV; long-term benefit unproven - led directly to PEXIVAS

PEXIVAS Trial - Practice-Changing Study on Plasma Exchange and GC Dosing

Parameter	Detail
Study	PEXIVAS (Walsh et al., NEJM 2020; Jayne et al. full report PMID: 36155131)
Design	International (95 centres, Europe/North America/Australia/Japan), open-label, 2×2 factorial RCT
Population	704 patients with GPA or MPA; GFR <50 mL/min/1.73 m² OR diffuse alveolar haemorrhage (DAH)
Arms	(1) PE × 7 sessions within 14 days vs. no PE; AND (2) standard-dose GC vs. reduced-dose GC (60% less cumulative oral GC by month 6)
Primary outcome	Composite all-cause mortality + ESKD
PE result	Primary endpoint: PE 28% vs. no PE 31% (HR 0.86; 95% CI 0.65-1.13; p = 0.3) - NO BENEFIT
Reduced GC result	Non-inferiority met (risk difference 2.3%, p = 0.5); serious infections: IRR 0.69 (0.52-0.93) - significantly fewer
DAH subgroup (2024)	Fussner et al., AJRCCM 2024 [PMID: 38346237]: PE not beneficial even in DAH subgroup
Early kidney function (2025)	Odler et al., Kidney Int 2025 [PMID: 39708998]: PE improved early kidney recovery only transiently
Conclusion	Plasma exchange no longer routinely recommended in AAV - even for severe renal disease or DAH. Reduced-dose GC is the new standard (same efficacy, fewer infections)

Firestein & Kelley's: "The reduced-dose regimen met its noninferiority endpoint for the efficacy outcome of death or end-stage renal disease, and patients in the lower-dose group had fewer infections (IRR 0.69; CI 0.52–0.93)."
2025 BSR: "Adjunctive plasmapheresis is not routinely recommended for pulmonary haemorrhage without severe kidney involvement."

4. Glucocorticoid Reduction Trials

PEXIVAS Reduced-Dose GC Arm (see above)

Reduced-dose GC regimen achieves ~50% less cumulative oral GC in the first 6 months vs. standard, tapering to 5 mg/day by month 4-5 (PEXIVAS schedule). Non-inferior outcome, significantly fewer infections. This is now the recommended GC-reduction protocol for organ-threatening AAV.

LOVAS Trial - Low-Dose GC in Non-Severe AAV

Parameter	Detail
Study	LOVAS (Furuta et al., ARD 2021)
Design	RCT; Japan
Population	140 patients with non-severe (non-organ-threatening) AAV
Intervention	Standard prednisolone (1 mg/kg/day) vs. reduced prednisolone (0.5 mg/kg/day)
Primary endpoint	Remission at 6 months
Result	Reduced dose 71.0% vs. standard 69.2% - noninferiority met
Adverse events	Serious AEs: 18.8% vs. 36.9% (p = 0.02); serious infections: 7.2% vs. 20.0% (p = 0.04)
Conclusion	Reduced GC (0.5 mg/kg, LoVAS schedule) for non-severe AAV - same efficacy, fewer AEs

Firestein & Kelley's: "Thus it is probable that standard glucocorticoid schedules developed over the past 50 years have used unnecessarily high doses."

5. The ADVOCATE Trial - Avacopan as Glucocorticoid Replacement

Scientific Basis

Complement activation is central to AAV pathogenesis. ANCA-activated neutrophils generate C5a, which recruits and primes further neutrophils in a positive feedback loop. Avacopan is an oral, selective C5a receptor 1 (C5aR1/CD88) inhibitor - blocking this amplification loop without abolishing total complement function.

Phase II - CLEAR Trial (Jayne et al., JASN 2017)

67 patients; avacopan ± low-dose prednisone showed comparable efficacy to high-dose prednisone for remission induction. Supported phase III development.

Phase III - ADVOCATE Trial (Jayne et al., NEJM 2021) - Landmark

Parameter	Detail
Design	Phase III, double-blind, double-dummy, active-controlled, multinational RCT
Population	331 patients with newly diagnosed or relapsing GPA or MPA
Intervention	Avacopan 30 mg BD × 52 weeks (replacing prednisone taper) vs. Standard prednisone taper (45-60 mg/day, tapering over 26 weeks); both groups received background RTX or CYC per physician choice
Primary endpoint 1	Remission at week 26 (BVAS = 0)
Primary endpoint 2	Sustained remission at week 52
Week 26 result	Avacopan 72.3% vs. prednisone 70.1% (noninferiority: p < 0.0001)
Week 52 result	Avacopan 65.7% vs. prednisone 54.9% (superiority: p = 0.007)
GFR improvement	Avacopan +7.3 vs. prednisone +4.1 mL/min/1.73 m² - significant renal benefit
GC toxicity	Glucocorticoid Toxicity Index significantly lower with avacopan (Patel et al., Lancet Rheumatol 2023 [PMID: 38251609])
Quality of Life	Significant HRQoL improvements favouring avacopan (Strand et al., Lancet Rheumatol 2023 [PMID: 38251577]): SF-36 physical component, EQ-5D health utilities
Adverse events	Serious AEs: avacopan 42.4% vs. prednisone 45.5% (similar); liver enzyme elevations: 11% vs. 8%
Regulatory approval	FDA: October 2021; EMA: January 2022

Post-hoc ADVOCATE sub-analyses (2024-2025):

Elderly patients (≥65 years): Avacopan effective and well-tolerated (Geetha et al. Rheumatology 2025 [PMID: 40037556])
CYC background: Avacopan effective with both RTX and CYC (Geetha et al. RMD Open 2025 [PMID: 41052893])
Low GFR (<20 mL/min): Greater renal recovery benefit in most severely impaired patients
Respiratory disease: Effective in patients with respiratory tract AAV manifestations (Specks et al., ACR Open Rheumatol 2025)
2025 BSR Guidelines: Avacopan is now a recommended replacement for the prednisone taper as part of induction therapy for GPA/MPA (GRADE 1A).
2022 EULAR: Avacopan recommended as part of induction regimen for GPA/MPA.

6. Maintenance Trials

CYCAZAREM - Azathioprine vs. Cyclophosphamide for Maintenance

Parameter	Detail
Study	CYCAZAREM (Jayne et al., NEJM 2003)
Design	RCT, European Vasculitis Study Group (n = 144)
Population	GPA/MPA in remission after CYC + GC induction
Intervention	Continue oral CYC 1.5 mg/kg/day vs. switch to AZA 2 mg/kg/day at 3 months of remission
Result	Relapse at 18 months: CYC 15.5% vs. AZA 13.7% (p = NS); adverse events similar
Conclusion	AZA equivalent to CYC for maintenance - CYC not required beyond remission induction; AZA established as standard maintenance

WEGENT - Azathioprine vs. Methotrexate for Maintenance

Parameter	Detail
Study	WEGENT (French Vasculitis Study Group)
Design	RCT
Intervention	AZA 2 mg/kg/day vs. MTX 0.3 mg/kg/wk (max 25 mg) for maintenance
Result	No significant difference in relapse rate or toxicity between AZA and MTX
Conclusion	MTX as effective as AZA for maintenance; avoid in GFR <30 mL/min

IMPROVE - Mycophenolate Mofetil vs. Azathioprine

Parameter	Detail
Study	IMPROVE (Hiemstra et al., ARD 2010)
Design	RCT, European Vasculitis Study Group
Intervention	MMF 2 g/day vs. AZA 2 mg/kg/day
Result	MMF significantly inferior: higher relapse rate (HR 1.69; 95% CI 1.06-2.70)
Cancers	AZA arm: 2 bladder + 3 skin cancers; MMF arm: 1 skin cancer
Conclusion	MMF inferior to AZA for maintenance - not recommended as first-line; 2025 BSR recommends MMF only if RTX/AZA/MTX contraindicated/not tolerated

MAINRITSAN 1 - Rituximab vs. Azathioprine Maintenance - Landmark

Parameter	Detail
Study	MAINRITSAN (Guillevin et al., NEJM 2014)
Design	RCT, French Vasculitis Study Group
Population	115 patients with GPA, MPA, or renal-limited vasculitis in complete remission after CYC induction
Intervention	RTX 500 mg IV at day 0, day 14, then every 6 months × 18 months vs. AZA 2 mg/kg/day (tapered over 22 months)
Primary endpoint	Major relapse rate at 28 months
Result	Major relapses: RTX 5% vs. AZA 29% (p < 0.001)
60-month follow-up	Severe relapses off treatment: RTX 28.1% vs. AZA 50.6% (HR 2.51 for AZA, p = 0.003) - benefit persists but accelerates after stopping
Adverse events	Similar severe infections, malignancy
Conclusion	RTX greatly superior to AZA for maintenance; established RTX as preferred maintenance agent for AAV

MAINRITSAN 2 - Fixed vs. Tailored Rituximab Dosing

Parameter	Detail
Study	MAINRITSAN 2 (Terrier et al., Ann Intern Med 2021)
Design	RCT (n = 162)
Population	GPA/MPA in complete remission after CYC induction
Intervention	Fixed schedule: RTX 500 mg every 6 months vs. Tailored: RTX 500 mg upon CD19+ B-cell reappearance OR ANCA titer doubling
Result	Major relapse at 28 months: fixed 9.9% vs. tailored 17.3% (p = 0.22) - not significantly different
Infusions	Fixed: median 5; tailored: median 3 - fewer infusions with tailored
Conclusion	Tailored dosing non-inferior; reduces drug burden and infusion frequency

MAINRITSAN 3 - Extended RTX vs. Placebo (Post-Maintenance Extension)

Parameter	Detail
Study	MAINRITSAN 3 (Terrier et al., ARD 2021)
Design	RCT placebo-controlled extension
Population	Patients completing MAINRITSAN 2
Intervention	Continue RTX 500 mg biannually vs. placebo
Result	Major relapse-free survival: RTX 100% vs. placebo 87% (p = 0.009)
Adverse events	Similar
Conclusion	Extended maintenance beyond 2 years reduces relapse; supports longer-term RTX therapy

RITAZAREM - Rituximab vs. Azathioprine in Relapsing AAV

Parameter	Detail
Study	RITAZAREM (Smith et al., ARD 2019)
Design	RCT (n = 170)
Population	Relapsing ANCA vasculitis in remission after RTX induction (1 g × 2 doses) - key difference from MAINRITSAN 1
Intervention	RTX 1000 mg IV every 4 months × 5 doses (more frequent/higher dose than MAINRITSAN) vs. AZA 2 mg/kg/day
Primary endpoint	Relapse rate at 24 months
Result	During treatment: relapses 13/85 (RTX) vs. 32/85 (AZA); HR 0.35 (0.18-0.66)
Severe relapses	6 (RTX) vs. 17 (AZA)
Serious AEs	RTX 22% vs. AZA 36% during treatment period
36-month (off treatment)	Benefit sustained: HR 0.41 (0.27-0.61)
Conclusion	RTX markedly superior to AZA for relapsing AAV; higher RTX dose (1000 mg/4 months) supports use in higher-risk patients

Firestein & Kelley's: "Fewer relapses were seen in the rituximab group (HR, 0.35; 96% CI, 0.18–0.66). Including a follow-up period off treatment (to 36 months since enrollment), fewer relapses were still seen in the rituximab group (HR, 0.41; 95% CI, 0.27–0.61)."

B-Cell-Guided vs. ANCA-Guided RTX Maintenance (Zonozi et al. 2024)

Parameter	Detail
Study	Zonozi R et al., Ann Rheum Dis 2024 [PMID: 38123922]
Design	Prospective, single-centre, open-label RCT (n = 115)
Population	ANCA vasculitis in remission after ≥2 years of fixed-schedule RTX
Intervention	B-cell arm: RTX upon CD19+ B-cell repopulation vs. ANCA arm: RTX upon significant ANCA rise
Primary endpoint	Clinical relapse (modified BVAS/WG >0) by 36 months
Result	Relapse at 3 years: B-cell arm 4.1% vs. ANCA arm 20.5% (p = 0.045)
Safety	Total SAEs and deaths equivalent; COVID-19 SAEs higher in B-cell arm
RTX exposure	B-cell arm: 3.6 infusions vs. ANCA arm: 0.5 infusions per patient
Conclusion	B-cell-guided dosing is superior to ANCA-guided for preventing relapse; preferred long-term maintenance strategy

Duration Comparison - Karras et al. (AZA 24 vs. 48 Months)

AZA × 48 months had fewer relapses (22% vs. 63%) but more serious AEs (9 vs. 3 events) than × 24 months. Current guidelines recommend 24-48 months of maintenance, with individual risk assessment guiding duration.

7. TMP-SMX as Adjunct Maintenance

Stegeman et al. RCT (NEJM 1996)

Parameter	Detail
Population	GPA patients in remission
Intervention	TMP-SMX 960 mg BD vs. placebo
Result	TMP-SMX reduced relapses (23% vs. 40%; p = 0.02) and infections - especially upper respiratory
Mechanism	Eliminates nasal Staphylococcus aureus colonization - major relapse trigger in GPA
Conclusion	TMP-SMX recommended as adjunct in GPA with nasal/sinus involvement; not a substitute for standard immunosuppression; also provides Pneumocystis jirovecii prophylaxis

8. Trials in EGPA

Five Factor Score (FFS) - Risk Stratification Framework

The French Vasculitis Study Group developed the FFS to guide treatment intensity in EGPA. Poor prognostic factors (original FFS):

Serum creatinine >1.58 mg/dL
Proteinuria >1 g/day
Severe GI involvement
Cardiomyopathy
CNS involvement

FFS = 0: GC alone sufficient; FFS ≥1: Add CYC. Approximately 35% of FFS=0 patients relapse on GC taper alone.

MIRRA Trial - Mepolizumab in EGPA - Landmark

Parameter	Detail
Study	MIRRA (Wechsler et al., NEJM 2017)
Design	Phase III, double-blind, placebo-controlled RCT (n = 136)
Population	Relapsing or refractory EGPA on oral GC ≥7.5 mg/day
Intervention	Mepolizumab 300 mg SC every 4 weeks × 52 weeks vs. placebo; both with standard of care
Primary endpoints	(1) Accrued weeks of remission (BVAS = 0, prednisolone ≤4 mg/day); (2) Proportion in remission at weeks 36 and 48 combined
Remission rate	Mepolizumab: 28% vs. placebo: 3% in remission at weeks 36 and 48 (OR 5.91; p < 0.001)
Accrued remission	Significantly superior (26% vs. 8% of study weeks in full remission)
Steroid sparing	Daily prednisolone at 48 weeks: 4.0 mg (mepolizumab) vs. 10.0 mg (placebo)
Relapse	Lower relapse rate; eosinophil counts normalized
Adverse events	Similar; nasopharyngitis most common
Mechanism	Anti-IL-5 monoclonal antibody - reduces eosinophil survival and differentiation
Approval	FDA: December 2017; EMA: September 2018 - first targeted biologic for EGPA
Conclusion	Mepolizumab is the standard biologic therapy for relapsing/refractory EGPA; significant steroid-sparing

Rituximab for EGPA - Phase III Trial (Terrier et al. 2025)

Parameter	Detail
Study	Terrier B et al., Ann Intern Med 2025 [PMID: 40720835]
Design	Phase III, multicenter, double-blind, randomized, superiority RCT; France (n = 105)
Population	Newly diagnosed or relapsing EGPA (BVAS ≥3)
Intervention	RTX 1 g × 2 doses (2 weeks apart) + GC vs. conventional strategy (GC alone or GC + CYC for severe forms)
Primary endpoint	Remission (BVAS = 0 + prednisolone ≤7.5 mg/day) at day 180
Result	RTX 63.5% vs. control 60.4% (RR 1.05; 95% CI 0.78-1.42; p = 0.75) - not superior
Duration of remission	RTX 48.5 weeks vs. control 49.1 weeks (p = 0.41)
Adverse events	No significant differences
Conclusion	RTX not superior to conventional therapy for EGPA; unlike GPA/MPA, RTX is not first-line; ANCA-positive EGPA patients may benefit more (post-hoc observation)

Azathioprine vs. CYC for EGPA Maintenance

An earlier RCT (Guillevin et al.) confirmed AZA comparable to continued CYC for EGPA maintenance - similar to findings in GPA/MPA.

9. Emerging Trials (2022-2026)

ALEVIATE - Alemtuzumab in Refractory AAV

Parameter	Detail
Study	ALEVIATE (Gopaluni et al., Arthritis Res Ther 2022 [PMID: 35365179])
Design	Randomized, dose-ranging, phase II/III trial
Population	Refractory primary systemic vasculitis including AAV
Intervention	Alemtuzumab (anti-CD52 monoclonal antibody) at different doses
Result	Dose-dependent efficacy in refractory disease; significant infectious complications and secondary autoimmune events
Conclusion	Alemtuzumab may rescue refractory disease; significant toxicity profile; not standard care

IFX-1 - Anti-C5a Monoclonal Antibody

Unlike avacopan (which blocks the C5aR1 receptor), IFX-1 neutralizes the C5a ligand directly. Phase II trials ongoing (NCT03712345, NCT03895801). Results awaited.

Novel Anti-CD20 Agents

Obinutuzumab, ocrelizumab, ofatumumab - fully humanized anti-CD20 antibodies being evaluated to avoid RTX immunogenicity and serum sickness. Early phase data only; no AAV-specific RCTs yet.

Long-Term Avacopan Duration Trial (NCT06072482, Ongoing)

A 5-year RCT comparing avacopan × 5 years vs. × 1 year vs. placebo on top of SoC to determine optimal duration of C5aR inhibition.

10. Summary Table of Major Trials

Trial	Year	Design	Question	Key Result	Conclusion
CYCLOPS	2009	RCT	IV vs. oral CYC induction	Equal remission; IV = lower CYC dose	IV pulse CYC preferred
NORAM	2005	RCT	MTX vs. CYC (limited GPA)	MTX comparable at 6m; higher relapse rate	MTX only for limited non-renal disease
RAVE	2010	Phase III RCT	RTX vs. oral CYC induction	Non-inferior; RTX superior in relapsing	RTX = CYC; RTX preferred for relapsing/PR3
RITUXVAS	2010	RCT	RTX+2CYC vs. CYC (renal AAV)	No difference at 12m	RTX comparable to CYC in severe renal
WGET	2003	RCT	Etanercept in GPA	No benefit; increased solid tumors	TNF inhibitors contraindicated in AAV
MEPEX	2007	RCT	PE vs. IV MP (severe renal)	PE better early renal recovery	PE for dialysis-dependent; long-term unclear
PEXIVAS	2020	Factorial RCT (n=704)	PE vs. no PE; reduced vs. standard GC	PE: no benefit; reduced GC: non-inferior + fewer infections	PE not recommended; use reduced GC
LOVAS	2021	RCT	Reduced vs. standard GC (non-severe)	Non-inferior; fewer AEs with reduced dose	Reduced GC (0.5 mg/kg) for non-severe AAV
Stegeman	1996	RCT	TMP-SMX adjunct in GPA remission	Fewer relapses; fewer infections	TMP-SMX adjunct for upper tract GPA
CYCAZAREM	2003	RCT	AZA vs. CYC maintenance	Equivalent relapse/toxicity	AZA replaces CYC after remission
WEGENT	2008	RCT	AZA vs. MTX maintenance	Equivalent	AZA or MTX for maintenance
IMPROVE	2010	RCT	MMF vs. AZA maintenance	MMF inferior (higher relapse)	AZA preferred over MMF
MAINRITSAN 1	2014	RCT	RTX vs. AZA maintenance	RTX: 5% vs. AZA: 29% major relapse	RTX is preferred maintenance agent
MAINRITSAN 2	2021	RCT	Fixed vs. tailored RTX	No significant difference; tailored = fewer infusions	Tailored dosing acceptable
MAINRITSAN 3	2021	RCT	Extended RTX vs. placebo	RTX: 100% vs. placebo: 87% relapse-free survival	Extended maintenance beneficial
RITAZAREM	2019	RCT	RTX vs. AZA (relapsing AAV)	HR 0.35 favoring RTX	RTX markedly superior in relapsing disease
B-cell vs ANCA-guided (Zonozi 2024)	2024	RCT	B-cell vs. ANCA-triggered RTX	B-cell: 4.1% vs. ANCA: 20.5% relapse	B-cell guided dosing preferred
ADVOCATE	2021	Phase III RCT	Avacopan vs. prednisone taper	Superior at W52; better QoL/renal function	Avacopan replaces prednisone taper
MIRRA	2017	Phase III RCT	Mepolizumab vs. placebo (EGPA)	28% vs. 3% remission; major steroid-sparing	Mepolizumab first-line for relapsing EGPA
RTX for EGPA (Terrier 2025)	2025	Phase III RCT	RTX vs. conventional (EGPA)	Not superior	RTX not first-line in EGPA
ALEVIATE	2022	Phase II/III RCT	Alemtuzumab in refractory AAV	Efficacy but significant toxicity	Reserved for refractory disease

11. Current Guideline Recommendations (2025 BSR / 2022 KDIGO / 2022 EULAR)

Induction of Remission (GPA/MPA)

IV pulsed CYC or RTX + GC for all active GPA/MPA (GRADE 1A)
RTX preferred for relapsing disease (GRADE 1B)
CYC + RTX combination may be considered for life/organ-threatening disease
GC: PEXIVAS reduced-dose regimen (target 5 mg/day by month 4-5); IV methylprednisolone pulses NOT routinely recommended
Avacopan (30 mg BD × 52 weeks) replaces prednisone taper as part of induction (GRADE 1A, BSR 2025)

Maintenance of Remission (GPA/MPA)

RTX 500-1000 mg every 4-6 months preferred (GRADE 1)
B-cell-guided dosing preferred over ANCA-guided dosing
Alternatives: AZA 2 mg/kg/day or MTX 0.25-0.3 mg/kg/wk
MMF only if RTX/AZA/MTX not tolerated
Duration: 24-48 months (risk-stratified)

EGPA

GC alone for FFS = 0; CYC + GC for FFS ≥1
Mepolizumab (300 mg SC every 4 weeks) for relapsing/refractory EGPA
RTX not first-line in EGPA (negative phase III RCT, 2025)

Key References

Textbooks:

Firestein & Kelley's Textbook of Rheumatology (2022), Chapters 86-87
Comprehensive Clinical Nephrology 7th Ed., Chapter 26
Brenner & Rector's The Kidney (2-Vol), Chapters 18-19
NKF Primer on Kidney Diseases 8th Ed., Chapter 2
Goldman-Cecil Medicine (2022), Chapter 69
Harrison's Principles of Internal Medicine 22nd Ed. (2025), Chapter 375

Major Trial Publications:

Stone JH et al. (RAVE). NEJM 2010;363:221-232
Jones RB et al. (RITUXVAS). NEJM 2010;363:211-220
Walsh M et al. (PEXIVAS). NEJM 2020;382:622-631 [Full report: PMID 36155131]
Jayne DRW et al. (ADVOCATE). NEJM 2021;384:599-609
Guillevin L et al. (MAINRITSAN). NEJM 2014;371:1771-1780
Terrier B et al. (MAINRITSAN 2). Ann Intern Med 2021
Terrier B et al. (MAINRITSAN 3). ARD 2021
Smith RM et al. (RITAZAREM). ARD 2019
Wechsler ME et al. (MIRRA). NEJM 2017;377:1521-1531
Zonozi R et al. Ann Rheum Dis 2024 [PMID: 38123922]
Terrier B et al. (RTX in EGPA). Ann Intern Med 2025 [PMID: 40720835]
Fussner LA et al. (PEXIVAS-DAH). AJRCCM 2024 [PMID: 38346237]
Patel NJ et al. (ADVOCATE-GTI). Lancet Rheumatol 2023 [PMID: 38251609]
Strand V et al. (ADVOCATE-QoL). Lancet Rheumatol 2023 [PMID: 38251577]
Geetha D et al. (ADVOCATE elderly). Rheumatology 2025 [PMID: 40037556]

Generate a PowerPoint presentation summarizing all major AAV trials and current treatment algorithms

Reading File

Running Command

ls -la /home/daytona/workspace/ 2>/dev/null | head -20

Running Command

mkdir -p /home/daytona/workspace/aav-trials-pptx && ls /home/daytona/workspace/aav-trials-pptx/

Continue

Generate a PowerPoint presentation summarizing all major AAV trials and current treatment algorithms

Reading File

Write a detailed notes on Kikuchis disease from rheumatology textbooks and journals

Finding Sources

Searching PubMed

"Kikuchi disease" OR "Kikuchi-Fujimoto" AND lymphadenitis

Searching the Web

Kikuchi-Fujimoto disease 2024 2025 diagnosis treatment review rheumatology

Reading File

Reading Article

PMID: 36056828

Reading Article

PMID: 37383134

Finding Sources

Reading Article

PMID: 40610704

Searching PubMed

"Kikuchi-Fujimoto disease" AND pathogenesis AND etiology

Reading File

Reading Article

PMID: 39915303

Reading File

Searching PubMed

"Kikuchi" AND "histopathology" AND "diagnosis" AND lymphadenitis

Reading Article

PMID: 33169134

Reading Web Page

https://pmc.ncbi.nlm.nih.gov/articles/PMC10294163

I now have comprehensive information from multiple textbooks and recent journal literature to compile detailed notes on Kikuchi's disease. Let me now write the full notes.

Kikuchi-Fujimoto Disease (Histiocytic Necrotizing Lymphadenitis): Detailed Notes

Sources: Goldman-Cecil Medicine (2022), Rheumatology 2-Vol Set (Elsevier 2022), Firestein & Kelley's Textbook of Rheumatology (2022), Scott-Brown's Otorhinolaryngology (Vol 1 & 2), Harrison's Principles (22nd Ed. 2025), Quick Compendium of Clinical Pathology (5th Ed.); supplemented by key journal literature 2021-2025.

1. Introduction and Historical Background

Kikuchi-Fujimoto disease (KFD), also called histiocytic necrotizing lymphadenitis (HNL) or subacute necrotizing lymphadenitis, is a rare, benign, self-limiting disorder of lymph nodes of uncertain etiology. It is characterized by regional (typically cervical) lymphadenopathy accompanied by fever and, in severe cases, systemic constitutional symptoms.

The disease was simultaneously and independently described in Japan in 1972 by:

Masahiro Kikuchi - described it as "lymphadenitis showing focal reticulum cell hyperplasia with nuclear debris and phagocytosis"
Y. Fujimoto - reported similar cases as "cervical subacute necrotizing lymphadenitis"

It is classified in the WHO-5 (5th edition WHO Classification of Haematological Neoplasms, 2022) under the new category of "tumor-like lesions with T-cell predominance" - a group of non-neoplastic T-cell proliferations, reflecting its potential to mimic lymphoma.

Quick Compendium of Clinical Pathology: "The first of these entities is Kikuchi-Fujimoto disease (histiocytic necrotizing lymphadenitis), a lesion typically found in cervical lymph nodes of young females, consisting of partial nodal involvement by fields of karyorrhectic cell death, neutrophil-poor, in association with histiocytes (anomalously myeloperoxidase+), plasmacytoid dendritic cells (CD123+), and T cells (CD8+)."
Goldman-Cecil Medicine: "Kikuchi disease (histiocytic necrotizing lymphadenitis) is a disease of unknown origin that most commonly affects young women."

2. Epidemiology

Feature	Detail
Prevalence	Rare; exact prevalence unknown
Geographic distribution	Originally described in Japan and East Asia; now recognized worldwide; higher reported frequency in Asian populations
Sex predilection	Predominantly females (F:M ratio approximately 3:1 to 4:1)
Age	Most commonly young adults (teens to 30s); mean age ~25-30 years; pediatric cases well-documented
Racial predilection	More common in Asians, but occurs in all ethnic groups
Recurrence rate	~3-4% of patients experience relapse (sometimes years later)

3. Etiology and Pathogenesis

The etiology of KFD remains unknown and debated. Three major hypotheses exist:

3a. Infectious Trigger Hypothesis

Multiple infectious agents have been proposed as triggers:

Viruses: Epstein-Barr virus (EBV), Human Herpesvirus-6 (HHV-6), HHV-7, HHV-8, cytomegalovirus (CMV), parvovirus B19, HTLV-1, HIV, enteroviruses, SARS-CoV-2
Bacteria: Yersinia, Brucella, Bartonella henselae (cat-scratch disease), Toxoplasma gondii
Evidence: HHV-6 genomes have been found within affected lymph nodes; viral particles have been identified ultrastructurally in lymphocytes and histiocytes
Recent data: SARS-CoV-2 infection is now recognized as a trigger for KFD - systematic review (Cahuapaza-Gutierrez et al. Clin Rheumatol 2025, PMID: 40610704) documented 16 new-onset KFD cases post-COVID-19 infection (mean age 27 years), and 36 cases following COVID-19 vaccination (predominantly mRNA vaccines - Pfizer-BioNTech 75%, Moderna 11%; mostly after first dose)

3b. Autoimmune Mechanism Hypothesis

Strongest currently favored pathogenetic model:

HLA class II gene associations: Specific HLA-DPA1 and HLA-DPB1 alleles are overrepresented in KFD, suggesting genetic immune susceptibility
KFD shares striking clinical and histological overlap with SLE (see below)
Association with other autoimmune diseases (Hashimoto's thyroiditis, primary Sjogren's syndrome, APS)
Spontaneous resolution without treatment, pattern of recurrence, and concurrent autoimmune features all support immune dysregulation
Scott-Brown's Otorhinolaryngology: "An autoimmune aetiology has been proposed as some human leucocyte antigen (HLA) class II genes are more frequent in patients with KD. An association with systemic lupus erythematosus has also been reported."

3c. Cytotoxic T-Cell / Perforin-Mediated Apoptosis

The abundant apoptosis in KFD lymph nodes is driven by CD8+ cytotoxic T lymphocytes and plasmacytoid dendritic cells (pDCs)
Perforin-2 (MPEG1) is dramatically overexpressed in KFD (92% of cases in a 2025 study) - Lyapichev et al. Virchows Arch 2025 [PMID: 39915303]
Perforin-2 mediates pore formation and is essential for type I interferon-induced JAK/STAT signaling and elimination of viral infection
Hypothesis: an exaggerated cytotoxic immune response following viral infection drives the massive lymphocyte apoptosis characteristic of KFD
Type I interferon signaling is likely central (explaining the overlap with interferonopathies and SLE)

Integrated model: KFD likely represents an aberrant host immune response (possibly triggered by a virus or other infectious agent) in genetically susceptible individuals, mediated by CD8+ T cells, plasmacytoid dendritic cells, and activated histiocytes, leading to apoptotic lymphocyte death and necrosis.

4. Clinical Features

4a. Cardinal Manifestations

Feature	Frequency	Details
Lymphadenopathy	~100%	Firm to rubbery; predominantly cervical (posterior > anterior); may be tender; usually <3 cm
Fever	30-50%	Persistent or intermittent; low-grade to high fever (up to 39-40°C)
Tenderness of nodes	Common	May be painful on palpation
Weight loss	Severe cases	Constitutional symptom
Night sweats	Variable	Common in severe disease
Fatigue/malaise	Common	May precede lymphadenopathy

4b. Lymphadenopathy Distribution

Cervical: Most common (posterior cervical > anterior cervical) - 70-98% of cases
Generalized lymphadenopathy: Less common; suggests overlap with SLE or more severe disease
Other sites: Axillary, inguinal, mediastinal, mesenteric (reported)
Node size: Usually 1-3 cm; occasionally larger
Consistency: Firm to rubbery (not hard/fixed as in malignancy; not soft/fluctuant as in abscess)
Overlying skin: Usually uninvolved; rarely erythematous

4c. Cutaneous Manifestations

Skin involvement occurs in approximately 30-40% of KFD cases and includes:

Facial erythema (malar distribution - raises concern for SLE overlap)
Erythematous macules, papules, plaques - non-specific
Morbilliform/acneiform eruptions
Erythematous papulosquamous lesions
Urticarial lesions
Skin histology: Interface dermatitis pattern - histologically similar to cutaneous lupus
Cutaneous KFD (with skin biopsy showing similar necrotizing histiocytic infiltrate) is a distinct entity listed in Fitzpatrick's Dermatology

4d. Systemic and Extranodal Manifestations

System	Manifestation
Hepatic	Hepatomegaly; mildly elevated liver enzymes
Splenic	Splenomegaly (especially in severe/generalized disease)
Articular	Arthralgia, arthritis (reported)
Neurological	Aseptic meningitis; encephalitis (rare) - potentially fatal manifestations
Renal	Membranous nephropathy; mesangial nephritis (rare but documented; Falbo 2023)
Cardiac	Myocarditis; cardiomegaly (rare; case reports of KFD with cardiac involvement)
Ocular	Anaemic retinopathy (rare)
Haematological	Haemophagocytic lymphohistiocytosis (HLH) - association documented; overlap syndrome

4e. Special Populations

Pediatric KFD:

Less common than in adults; mean age ~10-14 years
Higher rates of fever (>90%), hepatosplenomegaly more common
Leukopenia more pronounced
May present as macrophage activation syndrome (MAS) in children
Overlapping diagnosis with HSS/KFD has been reported

KFD in males:

Similar clinical course but perhaps higher rate of systemic manifestations

5. Laboratory Findings

Investigation	Findings
Full blood count	Leukopenia (particularly lymphopenia) in ~50%; atypical lymphocytes may be present; thrombocytopenia uncommon
ESR	Elevated in most patients
CRP	Usually elevated
LDH	Elevated - marker of tissue necrosis and disease severity
Liver enzymes (ALT, AST)	Mildly elevated in ~30%
Serum ferritin	May be elevated (especially when associated with HLH)
ANA	Negative in pure KFD; positive ANA should prompt evaluation for SLE
Anti-dsDNA	Negative in pure KFD; if positive, suggests SLE
Complement (C3, C4)	Normal in KFD; low in SLE
Blood cultures	Negative (excludes bacterial lymphadenitis)
Bone marrow biopsy	Rarely needed; may show haemophagocytosis in HLH-KFD overlap

6. Histopathology - The Diagnostic Cornerstone

6a. Gross Pathology

Lymph node enlarged, pale, may show areas of necrosis on cut section
Capsule usually intact (unlike malignancy)
Partial nodal involvement - key feature

6b. Histological Phases (Proliferative → Necrotizing → Xanthomatous)

Three histological phases are recognized:

1. Proliferative (early) phase:

Paracortical expansion by a heterogeneous mixture of T cells, histiocytes, and plasmacytoid dendritic cells
Mitotically active, immunoblast-like cells
Crescentic and twisted nuclei

2. Necrotizing (active) phase - most common:

Patchy, well-circumscribed areas of coagulative/karyorrhectic necrosis in the paracortex
Abundant nuclear debris (karyorrhexis) - fragmented apoptotic nuclei
ABSENCE of neutrophils - a cardinal distinguishing feature
Histiocytes engulfing karyorrhectic debris
CD8+ T cells and plasmacytoid dendritic cells predominate
Myeloperoxidase (MPO)-positive histiocytes (anomalous feature, as MPO is normally a granulocyte marker)
Plasmacytoid dendritic cells (CD123+, CD68+, CD43+) in large numbers

3. Xanthomatous (healing/resolving) phase:

Foamy xanthomatous histiocytes predominate
Decreasing necrosis
Less cellular activity

6c. Immunohistochemistry Profile

Marker	Expression
CD68	+ (histiocytes)
CD123	+ (plasmacytoid dendritic cells - prominent)
MPO	+ (histiocytes - aberrant)
CD8	+ (predominant T cells)
CD4	Variable/reduced
CD20	Few scattered B cells
Ki-67	High proliferation index
CD3	+ (T cells)
C4d endothelial staining	Negative in KFD (vs. positive in lupus lymphadenitis - key distinction)

Quick Compendium of Clinical Pathology: "...partial nodal involvement by fields of karyorrhectic cell death, neutrophil-poor, in association with histiocytes (anomalously myeloperoxidase+), plasmacytoid dendritic cells (CD123+), and T cells (CD8+)."

6d. Key Histological Distinction: KFD vs. Lupus Lymphadenitis

Histologically, KFD and lupus lymphadenitis can be nearly impossible to distinguish by routine staining. Important differentiating features:

Feature	KFD	Lupus Lymphadenitis
Mean age	~25 years	~33 years
Biopsy site	Cervical (most)	May be non-cervical more often
Generalized lymphadenopathy	Less common	More common (56% vs. 23%)
Necrosis area	Smaller, focal	Larger, more extensive
Histiocytic infiltrates in necrosis	Prominent	Less prominent
Interfollicular pattern	Uncommon (4%)	More common (26%)
Plasma cell infiltrates	Rare	More frequent
Xanthomatous infiltrates	Rare	Present in 32%
C4d endothelial staining	Negative	Positive (65% in necrotic area)
Hematoxylin bodies	Absent	Present (specific for SLE)

Yu et al., Rheumatology (Oxford) 2021 [PMID: 33169134]: C4d immunohistochemical staining in the necrotic area distinguishes lupus lymphadenitis from KFD with high sensitivity; machine learning integration further improves accuracy.

6e. Fine Needle Aspiration Cytology (FNAC)

Usually shows non-specific reactive lymphadenitis - not reliable for definitive diagnosis
May reveal crescentic histiocytes engulfing karyorrhectic debris (suggestive)
FNAC alone is insufficient; open/core biopsy is often required
Mahajan et al. 2023: "Fine needle aspiration cytology mostly has features of nonspecific reactive lymphadenitis and immunohistochemistry studies usually show variable features of uncertain diagnostic value. Since its diagnosis is exclusively from histopathology, it needs to be evaluated more carefully."

7. Diagnosis

7a. Diagnostic Approach

The diagnosis of KFD is exclusively confirmed by lymph node histopathology. No pathognomonic clinical or laboratory finding exists.

Recommended approach:

Clinical suspicion: Young female with cervical lymphadenopathy + fever + leukopenia
Exclude infection: Blood cultures, viral serology (EBV, CMV, toxoplasma, HIV)
Basic labs: FBC, ESR, CRP, LFTs, LDH, ANA, anti-dsDNA
Imaging: Ultrasound neck (assess node characteristics); CT neck/chest/abdomen if generalized
Lymph node biopsy (excisional/core): For histopathology + immunohistochemistry
Evaluate for SLE (mandatory): ANA, anti-dsDNA, complement, urinalysis, renal function
Long-term follow-up for SLE development

7b. Clinical Diagnostic Criteria (No Validated Criteria)

No formal diagnostic criteria exist. Diagnosis requires histopathological confirmation of:

Karyorrhectic/coagulative paracortical necrosis
Absence of neutrophils
Histiocytic infiltration with karyorrhexis
CD8+ T cell and CD123+ plasmacytoid dendritic cell predominance

7c. Imaging

Ultrasound: Enlarged hypoechoic lymph nodes with increased vascularity; may help characterize node architecture; useful as screening
CT neck/chest/abdomen: Useful in generalized disease to assess extent; shows enlarged nodes without obvious necrotic breakdown; mediastinal adenopathy may be present
MRI: Not routinely used
PET scan: Shows FDG avidity in involved nodes (may mimic lymphoma on imaging - hence biopsy is essential)

8. Differential Diagnosis

KFD is frequently misdiagnosed. Key differentials:

Condition	Distinguishing Features
Non-Hodgkin lymphoma	Most important to exclude; persistent/progressive nodes; biopsy shows clonal lymphocyte proliferation; lymphoma markers positive
Hodgkin lymphoma	Reed-Sternberg cells on biopsy; CD30+, CD15+
SLE lymphadenitis	ANA/anti-dsDNA positive; complement low; hematoxylin bodies on biopsy; C4d+
Cat-scratch disease	History of cat exposure; Bartonella serology positive; stellate microabscesses with neutrophils
Infectious mononucleosis (EBV)	Heterophile antibody (Monospot) positive; EBV IgM positive; atypical lymphocytosis
Tubercular lymphadenitis	Caseating granulomas; AFB stain/culture; IGRA/TST positive
Toxoplasmosis	Toxoplasma serology positive; no necrosis (monocytoid B-cell hyperplasia pattern)
Still's disease (AOSD)	Quotidian fever, arthritis, salmon-colored rash, markedly elevated ferritin; lacks necrotizing lymphadenitis histology
Sarcoidosis	Non-caseating granulomas; serum ACE elevated; bilateral hilar adenopathy
Sweet's syndrome	Painful erythematous plaques; neutrophilic dermatosis histology
Drug-induced lymphadenopathy	Drug history; eosinophilia; drug lymphadenitis on biopsy
IgG4-related disease	IgG4+ plasma cell infiltration; storiform fibrosis; raised serum IgG4

Mahajan et al. 2023: "It is often mistaken for non-Hodgkin lymphoma while lupus lymphadenitis, cat-scratch disease, Sweet's syndrome, Still's disease, drug eruptions, infectious mononucleosis, and viral or tubercular lymphadenitis are other common differentials."

9. KFD and the SLE-KFD Relationship

This is a critical and clinically important overlap that every rheumatologist must know.

Nature of the Relationship

The association between KFD and SLE is well-established but complex, with three temporal patterns:

KFD preceding SLE (SLE develops later - sometimes months to years)
KFD concurrent with SLE (simultaneous diagnosis)
KFD in established SLE (SLE patient develops KFD as a feature)

Systematic review (Zaccarelli et al. Curr Rheumatol Rev 2023, PMID: 36056828): 43 studies included; overlap found with multiple autoimmune diseases. Autoimmune disease was "preceding" in 11 cases, "simultaneous" in 20 cases, and "post-KFD" in 8 cases.

Shared Clinicopathological Features

Feature	KFD	SLE
Female predominance	Yes	Yes
Young adults	Yes	Yes
Cervical lymphadenopathy	Dominant feature	Common feature
Fever	Yes	Yes
Malar rash	Sometimes	Classic
Interface dermatitis (skin biopsy)	Yes	Yes
Paracortical necrosis without neutrophils	Yes	Yes
Absence of significant immune complex deposition	Yes	Variable
Response to steroids	Yes	Yes

Why the Relationship Matters Clinically

KFD can be the presenting manifestation of SLE - patients who appear to have isolated KFD may evolve to full SLE
Lupus lymphadenitis and KFD are histologically very similar - C4d immunostaining helps distinguish
ALL patients with KFD should be:
- Tested for ANA, anti-dsDNA, complement, urinalysis
- Monitored long-term for development of SLE
- Rheumatology 2022 Elsevier: "patients who present with Kikuchi syndrome should be investigated further for SLE and be monitored long term"
The autoimmune overlap includes: JIA (reported), Sjögren's syndrome, antiphospholipid syndrome, Hashimoto's thyroiditis, systemic sclerosis

HLH-KFD Association

Haemophagocytic lymphohistiocytosis (HLH) can occur in association with KFD, particularly in severely ill patients and children presenting with macrophage activation syndrome. This underscores the importance of serum ferritin and bone marrow assessment in severe or atypical presentations.

10. COVID-19 and KFD (Recent Update)

A systematic review (Cahuapaza-Gutierrez et al. Clin Rheumatol 2025 [PMID: 40610704]; PROSPERO CRD42024522470) analyzed 52 patients:

Post-COVID-19 infection KFD (n=16):

Mean age: 27.25 ± 16.87 years
Manifestations: fever, fatigue, cough, weight loss
All cases resolved with supportive care; no mortality

COVID-19 vaccine-associated KFD (n=36):

Mean age: 30.8 ± 12.63 years
Predominantly female
mRNA vaccines: Pfizer-BioNTech (75%), Moderna (11.1%)
Mostly after first dose (75%)
Cervical lymphadenopathy predominant in both groups
Favorable outcomes in all cases

Conclusion: SARS-CoV-2 is a recognized new trigger for KFD. Vaccine-associated KFD is rare and self-limiting.

11. Natural History and Prognosis

KFD is typically self-limiting, resolving within 1-4 months (range: 2 weeks to 6 months)
Most patients recover completely without specific treatment
Recurrence: Occurs in ~3-4% of patients; may recur months to years later; recurrent episodes are generally milder
Mortality: Extremely rare; reported only in cases with severe neurological involvement (aseptic meningoencephalitis), massive HLH, or cardiac involvement
Goldman-Cecil Medicine: "Treatment is symptomatic, and manifestations usually resolve within weeks or months."
Firestein & Kelley's: "Kikuchi-Fujimoto disease, characterized by cervical lymphadenopathy, fever, and weight loss, may mimic SLE."

Prognostic factors for a more prolonged or severe course:

Generalized lymphadenopathy
High fever
Marked leukopenia
Elevated LDH
Association with SLE or HLH
Neurological manifestations

12. Treatment

Treatment is largely symptomatic and supportive, as KFD is self-limiting. No RCTs exist; management is based on case series and expert opinion.

12a. General Measures

NSAIDs: First-line for symptomatic relief - reduce fever, pain, and lymph node tenderness
Analgesics/antipyretics as needed
Rest and reassurance

12b. Corticosteroids

Indicated for severe disease: High fever unresponsive to NSAIDs, severe systemic symptoms, neurological involvement, HLH-associated KFD, or SLE-overlap cases
Dose: Prednisolone 0.5-1 mg/kg/day, typically for 2-4 weeks then tapered
Response is generally good
Mahajan et al. 2023: "Treatment with systemic corticosteroids, hydroxychloroquine, or antimicrobial agents mostly remains empirical."

12c. Hydroxychloroquine (HCQ)

Used especially in cases with SLE overlap or when steroids are not well-tolerated
May help prevent relapse
Dose: 200-400 mg/day
Particularly useful given shared pathogenesis with SLE/interferonopathy

12d. IV Immunoglobulin (IVIG)

Reported in severe or steroid-refractory KFD
May be considered in HLH-associated KFD

12e. What Does NOT Work

Antibiotics: KFD does not respond to antibiotics - important to avoid unnecessary antibiotic courses
Scott-Brown's Otorhinolaryngology: "The disease is usually self-limiting and does not respond to antibiotic therapy."

12f. Treatment Algorithm

KFD Confirmed by Biopsy
        |
        ├── Mild disease (fever + cervical lymphadenopathy only)
        |       └── NSAIDs/analgesics + observation
        |           → Resolve in 1-4 months
        |
        ├── Moderate-severe disease (high fever, systemic symptoms, leukopenia)
        |       └── Corticosteroids (prednisolone 0.5 mg/kg) ± HCQ
        |
        ├── SLE overlap features (ANA+, anti-dsDNA+, cytopenias)
        |       └── Treat as SLE + HCQ + consider corticosteroids
        |
        └── HLH-associated KFD (hyperferritinaemia, haemophagocytosis)
                └── HLH protocol + corticosteroids ± etoposide

13. Follow-Up Recommendations

Given the association with SLE, the following follow-up is recommended after a diagnosis of KFD:

Time Point	Action
At diagnosis	ANA, anti-dsDNA, complement (C3/C4), urinalysis, FBC, renal function
6 weeks	Repeat FBC, inflammatory markers; clinical reassessment
3-6 months	Reassess for SLE features; repeat ANA if initially negative
6-12 monthly × 2 years	Screen for SLE development; urinalysis, FBC, ANA
Any new symptoms	Prompt re-evaluation - new rash, renal involvement, serositis
Recurrence	Re-biopsy to confirm KFD; re-evaluate for SLE

14. Key Teaching Points and Clinical Pearls

"Young Asian woman + cervical lymphadenopathy + fever + leukopenia" = Think KFD first
Diagnosis is histopathological - biopsy is mandatory (FNAC is insufficient)
The absence of neutrophils in necrotic areas is the most important histological clue
KFD closely mimics lymphoma on imaging and FNAC - never diagnose lymphoma without excisional biopsy
Always screen for SLE in every KFD patient - may be the heralding presentation
C4d immunostaining distinguishes KFD (negative) from lupus lymphadenitis (positive)
KFD does NOT respond to antibiotics - avoid empirical antibiotic therapy
NSAIDs are first-line; reserve corticosteroids for severe/SLE-overlap disease
COVID-19 (infection and mRNA vaccination) is a recognized newer trigger
Perforin-2 overexpression (2025 data) suggests KFD is a virus-triggered cytotoxic immune response with massive apoptosis as the pathological hallmark
HLH can complicate KFD - check ferritin in severe cases
WHO-5 now classifies KFD under "tumor-like lesions with T-cell predominance" - reflecting lymphoma-mimicking potential

Key References

Textbooks:

Goldman-Cecil Medicine (2022), Chapter on Lymphadenopathy
Rheumatology 2-Vol Set (Elsevier, 2022), Chapter 117 (SLE - lymphatic involvement)
Firestein & Kelley's Textbook of Rheumatology (2022), Chapter on SLE manifestations
Quick Compendium of Clinical Pathology 5th Ed., Section 4.3.7.5.1
Scott-Brown's Otorhinolaryngology Head & Neck Surgery, Vol 1 & 2
Harrison's Principles of Internal Medicine 22nd Ed. (2025)

Key Journal Literature:

Mahajan VK et al. "Kikuchi-Fujimoto disease: A comprehensive review." World J Clin Cases 2023 [PMID: 37383134]
Zaccarelli F et al. "Kikuchi-Fujimoto Disease: A Distinct Pathological Entity but also an Overlap Autoimmune Syndrome." Curr Rheumatol Rev 2023 [PMID: 36056828]
Yu SC et al. "Distinguishing lupus lymphadenitis from Kikuchi disease based on clinicopathological features and C4d immunohistochemistry." Rheumatology (Oxford) 2021 [PMID: 33169134]
Cahuapaza-Gutierrez NL et al. "Kikuchi-Fujimoto in the light of the COVID-19: infection and vaccination - A systematic review." Clin Rheumatol 2025 [PMID: 40610704]
Lyapichev KA et al. "Perforin-2 is overexpressed in Kikuchi-Fujimoto disease." Virchows Arch 2025 [PMID: 39915303]

This is a shared conversation. Sign in to Orris to start your own chat.